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Background: Recent attention has been given to subclinical hypothyroidism, defined as an elevation of TSH (4.5-10
uIU/L) with T4 and T3 levels still within the normal range. Controversy exists about the proper lower limit of TSH
that defines patients in the subclinical hypothyroidism range and about if/when subclinical hypothyroidism should
be treated. Additional data are needed to examine the relationship between markers of thyroid function in the
subclinical hypothyroidism range, biomarkers of health and ultimately health outcomes.
Objective: We aimed to assess the relationship between serum TSH levels in the 0.5-10 uIU/L range and serum
cortisol in a cohort of healthy young men and women without clinical evidence of hypothyroidism. Based on data
in frank hypothyroidism, we hypothesized that serum TSH levels would be positively correlated with serum cortisol
levels, suggesting derangement of the cortisol axis even in subclinical hypothyroidism.
Methods: We conducted a cross sectional study in 54 healthy, young (mean 20.98 +/− 0.37 yrs) men (19) and
women (35). Lab sessions took place at 1300 hrs where blood was drawn via indwelling catheter for later
assessment of basal serum TSH, free T3, free T4, and cortisol levels.
Results: All but 1 participant had free T3 levels within the normal reference intervals; free T4 levels for all
participants were within the normal reference intervals. Linear regression modeling revealed that TSH levels in the
0.5-10 uIU/L were significantly and positively correlated with cortisol levels. This positive TSH-cortisol relationship
was maintained below the accepted 4.5 uIU/L subclinical hypothyroid cutoff. Separate regression analyses
conducted by systematically dropping the TSH cutoff by 0.50 uIU/L revealed that the TSH-cortisol relationship was
maintained for TSH levels (uIU/L) ≤4.0, ≤3.5, ≤3.0, and ≤2.5 but not ≤2.0. Linear regression modeling did not reveal
a relationship between free T3 or free T4 levels and cortisol levels.
Conclusions: Results suggest a positive relationship between TSH and cortisol in apparently healthy young
individuals. In as much as this relationship may herald a pathologic disorder, these preliminary results suggest that
TSH levels > 2.0 uIU/L may be abnormal. Future research should address this hypothesis further, for instance
through an intervention study.
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Thyroxine (T4) and triiodothyronine (T3), together re-
ferred to as thyroid hormones, play an important role in
basal metabolism and the functioning of almost all tis-
sues and systems in the body [1]. In addition to T4 and
T3, thyroid stimulating hormone (TSH) secretion typic-
ally is maintained within relatively narrow limits via a
sensitive negative feedback loop in which TSH stimulates
the synthesis and release of thyroid hormones, that in
turn negatively feed back to the hypothalamus and an-
terior pituitary to limit further TSH release. Reduced
thyroid hormone levels existing together with elevated
TSH are an indication that the response of the thyroid
gland to TSH is impaired, i.e. primary hypothyroidism.
Recent attention has been given to subclinical
hypothyroidism, defined as a TSH elevation with T4 and
T3 levels still within the normal range. Subclinical
hypothyroidism is a common disorder; two large
population-based studies revealed that 4% to 8.5% of
individuals without known thyroid disease actually have
subclinical hypothyroidism as evidenced by a mildly ele-
vated TSH (i.e., 4.5-10 uIU/L) [2,3]. Complicating mat-
ters is the current controversy about the proper lower
limit of TSH that defines patients in the subclinical
hypothyroidism range (in other words, the upper limit of
the normal reference range for TSH) [4-8]. In apparently
healthy populations, the TSH distribution is skewed to-
wards the lower end of the reference range, with the
mean value typically being around 1.5 uIU/L, but with
the range extending from 0.5–4.5 uIU/L [8]. Therefore it
is possible that seemingly healthy individuals with TSH
levels in the upper end of this range may in fact have
elevated TSH in response to early thyroid gland failure
and also should be considered to have subclinical
hypothyroidism. This possibility is further supported
by the fact that many patients with TSH levels in
the 3.0–4.5 uIU/L range are positive for antithyroid
antibodies [6,8].
Untreated hypothyroidism can lead to increased body
weight, cognitive dysfunction, fatigue, abnormal serum
lipids, coronary heart disease, and for women recurrent
miscarriage, infertility, and possibly delayed cognitive de-
velopment in their children [1,9,10]. Much controversy
still exists regarding the extent to which clinically mean-
ingful consequences result from untreated subclinical
hypothyroidism or are due to TSH values in the upper
range of “normal” [4-8]. Indeed, by definition the only
abnormality found with subclinical hypothyroidism is a
mild to modest TSH elevation that is more sensitive
than either free T3 or free T4 in reflecting this condition
[4]. Most clinical guidelines recommend either close ob-
servation or a therapeutic trial of levothyroxine in
patients with TSH values in the 4.5-10 uIU/L range and
simply observation when the TSH result is in the rangeof 2.5-4.5 uIU/L [5,10]. These recommendations are
based on lack of conclusive evidence in either range of
definitive disease. Intervention studies that examine neu-
rocognitive symptoms in patients identified with sug-
gestive symptoms at baseline, as well as intervention
studies that focus on long-term outcomes such as ath-
erosclerosis, have not been carried out.
More research is therefore clearly needed in this area.
This preliminary study assessed the relationship between
serum TSH levels in the 2.5-10 uIU/L range and serum
cortisol in a cohort of healthy young men and women
with no clinical history of thyroid disease or other
underlying health conditions. It has long been known
that frank hypothyroidism causes elevated cortisol levels,
presumably due to both decreased clearance and blunted
negative feedback of cortisol on the hypothalamic-
pituitary-adrenal axis [11]. In the present study we
hypothesized that serum TSH levels would be positively




Participants were recruited through advertisements in
the local newspaper and flyers posted in the local com-
munity. Research staff through telephone-screening
interviews determined eligibility. Exclusion criteria
included a history of smoking (<1 year ago); diagnosed
heart disease, diabetes, stroke or other neurological dis-
orders or depression; significant medication use (blood
pressure, beta-blockers, inhaled beta agonists, hormonal
contraceptives, corticosteroid use within prior three
months, psychotropic medication use within prior eight
weeks; psychiatric hospitalization within past year; and
body mass index (BMI; kg/m2) > 32. BMI was confirmed
at the beginning of the study session. Women with a
partial or complete hysterectomy, tubal ligations, history
of menstrual irregularities, and who were pregnant or
lactating within the past 12 months were also excluded
from the study.
Thirty-five healthy women and 19 men, 18–30 years of
age (mean age 20.98 +/− 0.37 years), were eligible.
Women were randomly assigned to participate during
the late luteal (N=18) or follicular (N=17) phase of their
menstrual cycle because of menstrual phase effects on
cortisol levels [12]. Sex steroid assays confirmed cycle
phase with mean estradiol and progesterone levels for
the late luteal phase at 123.94 ± 22.72 pg/mL and
18.12 ± 3.41 ng/mL, respectively, and follicular phase
levels at 49.31 ± 6.13 pg/mL and 4.40 ± 0.82 ng/mL, re-
spectively. Thirty-eight (70.4%) of the participants identi-
fied themselves as Caucasian, 4 (7.4%) African
American, 4 (7.4%) Asian, 2 (3.7%) Hispanic, and
6 (10.7%) self-described as “other.” The Pennsylvania
Table 1 Mean serum TSH (uIU/L), free T3 (pg/mL), free T4
(ng/dL), and cortisol (ug/dL), and BMI (kg/m2) in men
(N=19) and in women during the luteal (N=18) and
follicular (N=14) phases of the menstrual cycle








TSH (uIU/L) 3.25 ± 0.44 2.34 ± 0.32 2.21 ± 0.26
Free T3 (pg/mL) 3.04 ± 0.11 2.89 ± 0.11 3.29 ± 0.52
Free T4 (ng/dL) 1.28 ± 0.04 1.25 ± 0.05 1.28 ± 0.04
Cortisol (ug/dL) 14.77 ± 1.21 9.35 ± 0.87 10.94 ± 1.17
BMI (kg/m2) 23.37 ± 0.72 23.73 ± 0.80 23.23 ± 0.82
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and approved all study procedures.
Procedure
Lab sessions took place at 1300 hrs at The Pennsylvania
State University General Clinical Research Center. Fol-
lowing informed consent and the measurements of body
weight and height, a nurse practitioner confirmed health
status and study eligibility. An indwelling catheter was
then inserted and, and after a 10-minute acclimation
period a 20cc blood sample was drawn and allowed to
sit at room temperature for 15 minutes. Samples were
centrifuged at 1500 X g at 4 degrees C for 15 minutes.
Serum was stored at −80 C until hormone analysis was
performed. Participants were compensated for their
time.
Hormonal analyses
Cortisol, TSH, estradiol, and progesterone levels were
determined at The Pennsylvania State University’s GCRC
using commercially available enzyme immunoassay kits
(Diagnostic Systems Laboratories, Inc., Webster, Texas).
Low-end assay sensitivity for cortisol, TSH, estradiol and
progesterone were as follows: 0.1 ug/dL (cortisol), 0.01
uIU/L (TSH), 7 pg/mL (estradiol), and 0.13 ng/mL (pro-
gesterone). Intra-assay and inter-assay imprecision for
all analytes averaged less than 10%; all samples were
tested in duplicate in a single assay batch. Duplicate test
values that varied by more than 5% were subject to re-
peat testing. The average of the duplicate test results
is reported below. Serum free T3 (FT3) and free T4
(FT4) levels were determined by radioimmunoassay
with reagents obtained from Siemens Medical Solutions
(Hollidaysburg, PA).
Statistical analyses
Statistical analyses were performed using SPSS, version
17.0 (Chicago, IL, US). Means are reported plus or
minus standard error of the mean. Statistical significance
levels were set at α=0.05 and two-tailed tests were used.
Results
Serum free T4 levels for all participants were within the
normal reference interval (i.e., 0.7-1.8 ng/dl see Table 1).
Serum free T3 levels fell within the normal reference
interval (i.e., 2.0-5.0 pg/mL) for all but 1 participant
whose level was elevated (11.5 pg/mL). We included this
participant in our analyses because FT3 results are less
reliable than FT4 results due to the low concentration
found in the circulation and TSH and FT4 were within
the normal range for this participant (TSH=3.61 uIU/L;
FT4=1.6 ng/dl). It is important to note that the following
results do not change as a result of removing this
participant from the analyses. Overall, these FT3 andFT4 data confirm the absence of overt clinical
hypothyroidism in our participants.
Cortisol and TSH results were not normally distribu-
ted (i.e., were skewed). Therefore, a natural logarithmic
transformation was applied to the cortisol and TSH
values e.g., [13,14], which resulted in a normal distribu-
tion of the data. Thus, the transformed data were used
for analyses, but the raw data are reported in Table 1 for
clarity. Two serum TSH level ranges were tested in the
analyses: [1] levels below the cutoff for overt
hypothyroidism (<10 uIU/L) and [2] levels below the
cutoff for subclinical hypothyroidism (<4.5 uIU/L). Over-
all, serum TSH levels varied widely among participants
who otherwise presented to the study as healthy. Con-
sistent with U.S. prevalence rates [2,3], approximately
9% of the sample population (N=5) demonstrated mildly
elevated TSH levels (4.5-10 uIU/L); these participants
typically would be categorized as having subclinical
hypothyroid disease in a medical setting [10]. Three add-
itional participants (all women in the follicular phase)
had serum TSH levels indicative of overt clinical
hypothyroidism (TSH ≥10 uIU/L) and were excluded
from analyses because we were interested in the rela-
tionship between TSH and cortisol among healthy indi-
viduals. It is important to note that the following results
interpretation did not change as a result of this exclu-
sion. Serum TSH levels from the final cohort (N=51)
ranged from 0.86-9.57 uIU/L (mean 2.64 ± 0.22 uIU/L).
Table 1 lists the average TSH and cortisol results by hor-
mone status group (± standard error of the mean) for
the final group. Cortisol levels were in the normal range
for early afternoon.
Separate one-way analyses of variance (ANOVAs) con-
firmed that TSH, FT3, FT4 levels, as well as body mass
index (BMI), across the 3 hormone status groups were
similar (see Table 1); data were therefore collapsed
across hormone status groups for the subsequent ana-
lyses. Body mass index was included as a covariate in
the analyses but it did not affect the statistical
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in the final models.
Simple linear regression modeling revealed that serum
TSH levels ≤ 10 uIU/L significantly predicted serum
cortisol levels [β=0.33, t(50)=2.80, p<0.05.]. This
TSH-cortisol relationship also held for subjects who
were nominally euthyroid (i.e., below the subclinical
hypothyroid cutoff, i.e., TSH ≤ 4.5 uIU/L) [β=0.49, t(46)
=3.35, p<0.05]. To further explore the TSH-cortisol rela-
tionship, we ran separate regression analyses by system-
atically dropping the TSH cutoff by 0.50 uIU/L. The
positive TSH-cortisol relationship was maintained for
TSH levels: [1] ≤ 4.0 uIU/L [β=0.53, t(45)=3.51, p<0.05],
[2] ≤ 3.5 uIU/L [β=0.23, t(40)=2.38, p<0.05], [3] ≤ 3.0
uIU/L [β=0.34, t(37)=3.19, p<0.05], and [4] ≤ 2.5 uIU/L
[β=0.68, t(30)=2.89, p<0.05]. Serum TSH levels below
2.0 uIU/L were not significantly associated with serum
cortisol levels [β=0.33, t(18)= 6.53, ns]. In other words,
serum cortisol levels among individuals with TSH levels
>2.0 uIU/L (N=31) were significantly higher than among
those individuals with TSH levels ≤ 2.0 uIU/L (N=20)
[13.83 ± 0.93 ug/dL vs. 8.66 ± 0.59 ug/dL, respectively, F
(1,48)=14.24, p<0.0001]. There was no relationship
observed between either FT3 or FT4 and cortisol levels.Discussion
We examined the relationship between TSH levels and
cortisol in a preliminary study of young, healthy adults
without known thyroid disease or other underlying
health conditions. The positive relationship between
serum TSH and cortisol levels in a healthy population is
a compelling new finding that is consistent with and
extends the observation that frankly hypothyroid
patients have frankly elevated cortisol levels [11].
These preliminary results raise important questions –
such as whether this relationship is pathologic or
physiologic and what the mechanism(s) involved in this
relationship may be. While in frank hypothyroidism, it is
hypothyroidism that causes elevation of cortisol by re-
ducing peripheral disposal and blunting feedback of
cortisol on the hypothalamic-pituitary-adrenal axis
[11], our cross sectional data do not elucidate whether
the same mechanisms hold true for TSH levels in the
high normal and low elevated range. Thus more de-
finitive population-based and intervention studies are
now needed to confirm this finding and answer these
questions.
Another potential explanation for the positive TSH-
cortisol relationship is that hypothyroidism - subclinical
or clinical - is associated with subtle metabolic stress.
Metabolic stress could be imposing an effect on the
adrenocorticotropin hormone-adrenal axis leading to an
increase in stress hormone (i.e., cortisol) release andproduction. This hypothesis should be confirmed
through the measurement of other stress hormones in-
cluding the catecholamines, norepinephrine/epinephrine,
and/or prolactin.
Although limited in sample size, our findings demon-
strate that a positive relationship exists between TSH
and cortisol that is maintained down to a TSH level of
2.5 uIU/L (but not below). This observation raises the
possibility that negative health effects of mild, subclinical
hypothyroidism with mild to modest elevations in TSH
may begin at levels much lower than those currently
considered abnormal based on assigned normal refer-
ence range values with an upper reference level of
4.5 uIU/L.
Chronic elevations in serum cortisol and hypothyroidism
(including subclinical hypothyroidism) have been separ-
ately linked with increased rates of depression, anxiety,
and poor cognitive functioning e.g., [15-17]. Thus, the as-
sociation between TSH levels and cortisol suggests at least
the possibility of a novel pathway through which
hypothyroidism (both clinical and subclinical) may pro-
mote poor mental health; or hypothyroidism and an ele-
vated cortisol level could be synergistic on mental health.
It is possible that the relationship described in this
paper is physiologic rather than representative of path-
ology. Indeed, a failure to observe a relationship between
TSH and cortisol for TSH < 2.5uIU/L may be a matter
of methodology (assay accuracy at the lower levels, stat-
istical power) rather than an indication that a relation-
ship does not exist at those lower levels. Additional,
larger clinical studies are needed that also include repeat
TSH, FT3, FT4, cortisol, and catecholamine measure-
ments to validate the reliability of the TSH-cortisol
relationship.
A strength of this preliminary study is that we also
measured FT3 and FT4 levels in this cohort of young,
healthy individuals. Interestingly, while our results dem-
onstrate that subtle elevations in TSH are associated
with higher basal cortisol levels, this relationship is not
apparent for FT3 or FT4 levels. One plausible explan-
ation for the lack of an association between FT3 or FT4
and cortisol is that changes in FT3 and FT4 are slow to
reflect subclinical hypothyroidism in the circulation be-
cause of adjustments made at the end organ level in
both synthesis and metabolism of thyroid hormones [4].
In addition, changes in TSH are 10 times more sensitive
in reflecting an abnormality in thyroid hormone homeo-
stasis compared to FT3 or FT4 [4]. Similar to our find-
ing, other studies of subclinical hypothyroidism typically
report a relationship between the biomarker of interest
(e.g., cholesterol) and TSH, but not FT3 or FT4 [18].
However, it is still possible that mechanistically the rela-
tionship that we are here reporting is indeed between T3
and/or T4 and cortisol, but that measurement of FT4
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effects at the tissue level.
Our results and those of Iranmanesh et al. [11] for
frank hypothyroidism suggest effects of the thyroid axis
on the adrenal axis where hypothyroidism causes hyper-
cortisolemia. It is of interest to consider these observa-
tions together with the well-established opposite effects,
i.e. effects of the adrenal axis on thyroid function. Thus
when cortisol levels are manipulated through pathologic
as well as physiologic ranges, a negative relationship is
found between cortisol and TSH. Both exogenous and
endogenous (i.e. Cushing’s Syndrome, stress) corticoster-
oids suppress TSH [19-22] while low cortisol levels ele-
vate TSH [23,24]. These studies all taken together
suggest a physiologic feedback loop where lower thyroid
function increases cortisol, but cortisol feeds back to re-
duce TSH; this hypothesis is consistent with the obser-
vations that in the case of primary hypothyroidism
(elevated TSH) cortisol is elevated, but in the setting of
primarily elevated cortisol TSH is suppressed. Clearly
further clinical studies, for instance studies that incre-
mentally administer TSH and evaluate cortisol levels,
are needed in order to better understand the mechan-
isms involved in the TSH-cortisol relationship.
In summary these initial data, that add to what is
already known about frank hypothyroidism and cortisol,
demonstrate a potentially important relationship be-
tween TSH and cortisol in apparently healthy young
individuals. The finding that this relationship appears to
hold in the controversial TSH range of 2.5-10 uIU/L,
but not below, is compelling and requires further scien-
tific and clinical investigation.
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